Functions of tumorigenic and migrating cancer progenitor cells in cancer progression and metastasis and their therapeutic implications

Cancer and Metastasis Reviews

Volumn 26, Issue 1, 2007, Pages 203-214

  Mimeault, Murielle ^a   Batra, Surinder K ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cancer progenitor cells; Invasion; Metastasis; Stromal microenvironment; Targeting therapies; Tumor growth

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CISPLATIN; CURCUMIN; DOXORUBICIN; ETOPOSIDE; GENISTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; POLYPHENOL; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; RETINOID; RETINOID DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BONE MARROW; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CELL FUNCTION; CELL MIGRATION; CYTOKINE RELEASE; DIAGNOSTIC PROCEDURE; DRUG MECHANISM; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENE THERAPY; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO CULTURE; METASTASIS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROGENY; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; STEM CELL;

ANTINEOPLASTIC AGENTS; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; TUMOR STEM CELLS;

EID: 33947374762     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-007-9052-4     Document Type: Review

References (102)

1. Al-Hajj, M., & Clarke, M. F. (2004). Self-renewal and solid tumor stem cells. Oncogene, 23, 7274-7282.
2. Woodward, W. A., Chen, M. S., Behbod, F., & Rosen, J. M. (2005). On mammary stem cells. Journal of Cell Science, 118, 3585-3594.
3. Reya, T., & Clevers, H. (2005). Wnt signalling in stem cells and cancer. Nature, 434, 843-850.
4. Mimeault, M., & Batra, S. K. (2006). Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis, 27, 1-22.
5. Mimeault, M., & Batra, S. K. (2006). Recent advances on the significance of stem cells in tissue regeneration and cancer Therapies. Stem Cells, 24, 2319-2345.
6. Moore, K. A., & Lemischka, I. R. (2006). Stem cells and their niches. Science, 311, 1880-1885.
7. Li, L., & Neaves, W. B. (2006). Normal stem cells and cancer stem cells: The niche matters. Cancer Research, 66, 4553-4557.
8. Fuchs, E., Tumbar, T., & Guasch, G. (2004). Socializing with the neighbors: Stem cells and their niche. Cell, 116, 769-778.
9. Trosko, J. E., & Tai, M. H. (2006). Adult stem cell theory of the multi-stage, multi-mechanism theory of carcinogenesis: Role of inflammation on the promotion of initiated stem cells. Contributions to Microbiology, 13, 45-65.
10. Beachy, P. A., Karhadkar, S. S., & Berman, D. M. (2004). Tissue repair and stemcell renewal in carcinogenesis. Nature, 432, 324-331.
11. Fang, D., Nguyen, T. K., Leishear, K., Finko, R., Kulp, A. N., Hotz, S., et al. (2005). A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Research, 65, 9328-9337.
12. Sell, S. (2004). Stem cell origin of cancer and differentiation therapy. Critical Reviews in Oncology/Hematology, 51, 1-28.
13. Kastan, M. B., & Bartek, J. (2004). Cell-cycle checkpoints and cancer. Nature, 432, 316-323.
14. Li, L. C., Carroll, P. R., & Dahiya, R. (2005). Epigenetic changes in prostate cancer: Implication for diagnosis and treatment. Journal of the National Cancer Institute, 97, 103-115.
15. Bapat, S. A., Mali, A. M., Koppikar, C. B., & Kurrey, N. K. (2005). Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Research, 65, 3025-3029.
16. Brabletz, T., Jung, A., Spaderna, S., Hlubek, F., & Kirchner, T. (2005). Opinion: Migrating cancer stem cells - An integrated concept of malignant tumour progression. Nature Reviews. Cancer, 5, 744-749.
17. Vescovi, A. L., Galli, R., & Reynolds, B. A. (2006). Brain tumour stem cells. Nature Reviews. Cancer, 6, 425-436.
18. Mimeault, M., Brand, R. E., Sasson, A. A., & Batra, S. K. (2005). Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies. Pancreas, 31, 301-316.
19. Singh, S. K., Clarke, I. D., Terasaki, M., Bonn, V. E., Hawkins, C., Squire, J., et al. (2003). Identification of a cancer stem cell in human brain tumors. Cancer Research, 63, 5821-5828.
20. Al-Hajj, M., Wicha, M. S., ito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 100, 3983-3988.
21. Hope, K. J., Jin, L., & Dick, J. E. (2004). Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nature Immunology, 5, 738-743.
22. Collins, A. T., Berry, P. A., Hyde, C., Stower, M. J., & Maitland, N. J. (2005). Prospective identification of tumorigenic prostate cancer stem cells. Cancer Research 65, 10946-10951.
23. Wicha, M. S., Liu, S., & Dontu, G. (2006). Cancer stem cells: An old idea - A paradigm shift. Cancer Research, 66, 1883-1890.
24. Tai, M. H., Chang, C. C., Kiupel, M., Webster, J. D., Olson, L. K., & Trosko, J. E. (2005). Oct4 expression in adult human stem cells: Evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis, 26, 495-502.
25. Yu, H. M., Frank, D. E., Zhang, J., You, X., Carter, W. G., & Knudsen, B. S. (2004). Basal prostate epithelial cells stimulate themigration of prostate cancer cells. Molecular Carcinogenesis, 41, 85-97.
26. Bissell, M. J., & Radisky, D. (2001). Putting tumours in context. Nature Reviews. Cancer, 1, 46-54.
27. Rak, J. (2006). Is cancer stem cell a cell, or a multicellular unit capable of inducing angiogenesis? Medical Hypotheses, 66, 601-604.
28. Kalluri, R., & Zeisberg, M. (2006). Fibroblasts in cancer. Nature Reviews. Cancer, 6, 392-401.
29. Balkwill, F. (2004). Cancer and the chemokine network. Nature Reviews. Cancer, 4, 540-550.
30. Pollard, J. W. (2004). Tumour-educated macrophages promote tumour progression and metastasis. Nature Reviews. Cancer, 4, 71-78.
31. Li, H. C., Stoicov, C., Rogers, A. B., & Houghton, J. (2006). Stem cells and cancer: Evidence for bone marrow stem cells in epithelial cancers. World Journal of Gastroenterology, 12, 363-371.
32. Kuwana, M., Okazaki, Y., Kodama, H., Satoh, T., Kawakami, Y., & Ikeda, Y. (2006). Endothelial differentiation potential of human monocyte-derived multipotential cells. Stem Cells.
33. Santarelli, J. G., Udani, V., Yung, Y. C., Cheshier, S., Wagers, A., Brekken, R. A., et al. (2006). Incorporation of bone marrowderived Flk-1-expressing CD34+ cells in the endothelium of tumor vessels in the mouse brain. Neurosurgery, 59, 374-382.
34. Radisky, D. C., & Bissell, M. J. (2006). Matrix metalloproteinaseinduced genomic instability. Current Opinion in Genetics & Development, 16, 45-50.
35. Reiss, K., Ludwig, A., & Saftig, P. (2006). Breaking up the tie: Disintegrin-like metalloproteinases as regulators of cell migration in inflammation and invasion. Pharmacology & Therapeutics, 111, 85-1006.
36. Munshi, H. G., & Stack, M. S. (2006). Reciprocal interactions between adhesion receptor signaling and MMP regulation. Cancer Metastasis Reviews, 25, 45-56.
37. Deryugina, E. I., & Quigley, J. P. (2006).Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Reviews, 25, 9-34.
38. Thiery, J. P. (2002). Epithelial-mesenchymal transitions in tumour progression. Nature Reviews. Cancer, 2 , 442-454.
39. Gotzmann, J., Mikula, M., Eger, A., Schulte-Hermann, R., Foisner, R., Beug, H., et al. (2004). Molecular aspects of epithelial cell plasticity: Implications for local tumor invasion and metastasis. Mutation Research, 566, 9-20.
40. Yang, J., Mani, S. A., & Weinberg, R. A. (2006). Exploring a new twist on tumor metastasis. Cancer Research, 66, 4549-4552.
41. Zavadil, J., Cermak, L., Soto-Nieves, N., & Bottinger, E. P. (2004). Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. EMBO Journal, 23, 1155-1165.
42. Timmerman, L. A., Grego-Bessa, J., Raya, A., Bertran, E., Perez-Pomares, J. M., Diez, J., et al. (2004). Notch promotes epithelialmesenchymal transition during cardiac development and oncogenic transformation. Genes & Development, 18, 99-115.
43. Larue, L., & Bellacosa, A. (2005). Epithelial-mesenchymal transition in development and cancer: Role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene, 24, 7443-7454.
44. Huber, M. A., Kraut, N., & Beug, H. (2005). Molecular requirements for epithelial-mesenchymal transition during tumor progression. Current Opinion in Cell Biology, 17, 548-558.
45. Lee, J. M., Dedhar, S., Kalluri, R., & Thompson, E. W. (2006). The epithelial-mesenchymal transition: New insights in signaling, development, and disease. Journal of Cell Biology, 172, 973-981.
46. Vega, S., Morales, A. V., Ocana, O. H., Valdes, F., Fabregat, I., & Nieto, M. A. (2004). Snail blocks the cell cycle and confers resistance to cell death. Genes & Development, 18, 1131-1143.
47. Davies, M., Robinson, M., Smith, E., Huntley, S., Prime, S., & Paterson, I. (2005). Induction of an epithelial to mesenchymal transition in human immortal and malignant keratinocytes by TGF-beta1 involves MAPK, Smad and AP-1 signalling pathways. Journal of Cellular Biochemistry, 95, 918-931.
48. Kasper, M., Schnidar, H., Neill, G. W., Hanneder, M., Klingler, S., Blaas, L., et al. (2006) Selectivemodulation of hedgehog/GLI target gene expression by epidermal growth factor signaling in human keratinocytes. Molecular and Cellular Biology, 26, 6283-6298.
49. Bierie, B., & Moses, H. L. (2006). Tumour microenvironment: TGFbeta: The molecular Jekyll and Hyde of cancer. Nature Reviews Cancer, 6, 506-520.
50. Menke, A., Philippi, C., Vogelmann, R., Seidel, B., Lutz, M. P., Adler, G., et al. (2001). Down-regulation of E-cadherin gene expression by collagen type I and type III in pancreatic cancer cell lines. Cancer Research, 61, 3508-3517.
51. Savagner, P. (2001). Leaving the neighborhood: Molecular mechanisms involved during epithelial-mesenchymal transition. BioEssays, 23, 912-923.
52. Bergers, G., & Coussens, L. M. (2000). Extrinsic regulators of epithelial tumor progression: Metalloproteinases. Current Opinion in Genetics & Development, 10, 120-127.
53. Ii, M., Yamamoto, H., Adachi, Y., Maruyama, Y., & Shinomura, Y. (2006). Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Experimental Biology and Medicine (Maywood), 231, 20-27.
54. van de Vijver, M. J., He, Y. D., van't Veer, L. J., Dai, H., Hart, A. A., Voskuil, D. W., et al. (2002). A gene-expression signature as a predictor of survival in breast cancer. New England Journal of Medicine, 347, 1999-2009.
55. Buyse, M., Loi, S., van't V. L., Viale, G., Delorenzi, M., Glas, A. M., et al. (2006). Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. Journal of the National Cancer Institute, 98, 1183-1192.
56. Simon, R. (2006). Development and evaluation of therapeutically relevant predictive classifiers using gene expression profiling. Journal of the National Cancer Institute, 98, 1169-1171.
57. Pantel, K., & Woelfle, U. (2004). Micrometastasis in breast cancer and other solid tumors. Journal of Biological Regulators and Homeostatic Agents, 18, 120-125.
58. van Leenders, G. J., Aalders, T. W., Hulsbergen-van de Kaa, C. A., Ruiter, D. J., & Schalken, J. A. (2001). Expression of basal cell keratins in human prostate cancer metastases and cell lines. Journal of Pathology, 195, 563-570.
59. Yang, X. J., Lecksell, K., Gaudin, P., & Epstein, J. I. (1999). Rare expression of high-molecular-weight cytokeratin in adenocarcinoma of the prostate gland: A study of 100 cases of metastatic and locally advanced prostate cancer. American Journal of Surgical Pathology, 23, 147-152.
60. Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., et al. (2005). VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature, 438, 820-827.
61. Kucia, M., Reca, R., Miekus, K., Wanzeck, J., Wojakowski, W., Janowska-Wieczorek, A., et al. (2005). Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: Pivotal role of the SDF-1-CXCR4 axis. Stem Cells, 23, 879-894.
62. Neiva, K., Sun, Y. X., & Taichman, R. S. (2005). The role of osteoblasts in regulating hematopoietic stem cell activity and tumor metastasis. Brazilian Journal of Medical and Biological Research, 38, 1449-1454.
63. Engl, T., Relja, B., Marian, D., Blumenberg, C., Muller, I., Beecken, W. D., et al. (2006). CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins. Neoplasia, 8, 290-301.
64. Hideshima, T., Chauhan, D., Richardson, P., & Anderson, K. C. (2005). Identification and validation of novel therapeutic targets for multiple myeloma. Journal of Clinical Oncology, 23, 6345-6350.
65. Hart, C. A., Brown, M., Bagley, S., Sharrard, M., & Clarke, N. W. (2005). Invasive characteristics of human prostatic epithelial cells: Understanding the metastatic process. British Journal of Cancer, 92, 503-512.
66. Loberg, R. D., Day, L. L., Harwood, J., Ying, C., St John, L. N., Giles, R., et al. (2006). CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia, 8, 578-586.
67. Dimitroff, C. J., Descheny, L., Trujillo, N., Kim, R., Nguyen, V., Huang, W., et al. (2005). Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells. Cancer Research, 65, 5750-5760.
68. Tremblay, P. L., Auger, F. A., & Huot, J. (2006). Regulation of transendothelial migration of colon cancer cells by E-selectinmediated activation of p38 and ERK MAP kinases. Oncogene, 25, 6563-6573.
69. Witz, I. P. (2006). Tumor-microenvironment interactions: The selectin-selectin ligand axis in tumor-endothelium cross talk. Cancer Treatment and Research, 130, 125-140.
70. Bukholm, I. K., Nesland, J. M., & Borresen-Dale, A. L. (2000). Re-expression of E-cadherin, alpha-catenin and beta-catenin, but not of gamma-catenin, in metastatic tissue from breast cancer patients. Journal of Pathology, 190, 15-19.
71. Thiery, J. P. (2003). Epithelial-mesenchymal transitions in development and pathologies. Current Opinion in Cell Biology, 15, 740-746.
72. Fizazi, K., Yang, J., Peleg, S., Sikes, C. R., Kreimann, E. L., Daliani, D., et al. (2003). Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clinical Cancer Research, 9, 2587-2597.
73. Nuciforo, P., & Fraggetta, F. (2004). Cancer stem cell theory: Pathologists' considerations and ruminations about wasting time and wrong evaluations. Journal of Clinical Pathology, 57, 782.
74. Fehm, T., Sagalowsky, A., Clifford, E., Beitsch, P., Saboorian, H., Euhus, D., et al. (2002). Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clinical Cancer Research, 8, 2073-2084.
75. Kurbel, S. (2005). Selective reduction of estrogen receptor (ER) positive breast cancer occurrence by estrogen receptor modulators supports etiological distinction between ER positive and ER negative breast cancers. Medical Hypotheses, 64, 1182-1187.
76. Liu, S., Dontu, G., & Wicha, M. S. (2005). Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Research, 7, 86-95.
77. Romer, J., & Curran, T. (2005). Targeting medulloblastoma: Small-molecule inhibitors of the Sonic Hedgehog pathway as potential cancer therapeutics. Cancer Research, 65, 4975-4978.
78. Sun, S. Y., Hail, N. Jr., & Lotan, R. (2004). Apoptosis as a novel target for cancer chemoprevention. Journal of the National Cancer Institute, 96, 662-672.
79. Sarkar, F. H., & Li, Y. (2006). Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Research, 66, 3347-3350.
80. Shay, J. W., & Wright, W. E. (2002). Telomerase: A target for cancer therapeutics. Cancer Cell, 2, 257-265.
81. Sano, T., Kagawa, M., Okuno, M., Ishibashi, N., Hashimoto, M., Yamamoto, M., et al. (2005). Prevention of rat hepatocarcinogenesis by acyclic retinoid is accompanied by reduction in emergence of both TGF-alpha-expressing oval-like cells and activated hepatic stellate cells. Nutrition and Cancer, 51, 197-206.
82. Hope, K. J., Jin, L., & Dick, J. E. (2003). Human acute myeloid leukemia stem cells. Archives of Medical Research, 34, 507-514.
83. Kajita, M., McClinic, K. N., & Wade, P. A. (2004). Aberrant expression of the transcription factors snail and slug alters the response to genotoxic stress. Molecular and Cellular Biology, 24, 7559-7566.
84. Oloumi, A., McPhee, T., & Dedhar, S. (2004). Regulation of Ecadherin expression and beta-catenin/Tcf transcriptional activity by the integrin-linked kinase. Biochimica et Biophysica Acta, 1691, 1-15.
85. Jechlinger, M., Sommer, A., Moriggl, R., Seither, P., Kraut, N., Capodiecci, P., et al. (2006). Autocrine PDGFR signaling promotes mammary cancer metastasis. Journal of Clinical Investigation, 116, 1561-1570.
86. Biswas, S., Criswell, T. L., Wang, S. E., & Arteaga, C. L. (2006). Inhibition of transforming growth factor-beta signaling in human cancer: Targeting a tumor suppressor network as a therapeutic strategy. Clinical Cancer Research, 12, 4142-4146.
87. Park, C. C., Zhang, H., Pallavicini, M., Gray, J. W., Baehner, F., Park, C. J., et al. (2006). Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Research, 66, 1526-1535.
88. Hu, X. F., & Xing, P. X. (2005). Cripto as a target for cancer immunotherapy. Expert Opinion on Therapeutic Targets, 9, 383-394.
89. Orend, G., & Chiquet-Ehrismann, R. (2006). Tenascin-C induced signaling in cancer. Cancer Letters, 244, 143-163.
90. Wang, X., Ling, M. T., Guan, X. Y., Tsao, S. W., Cheung, H. W., Lee, D. T., et al. (2004). Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene, 23, 474-482.
91. Kwok, W. K., Ling, M. T., Lee, T. W., Lau, T. C., Zhou, C., Zhang, X., et al. (2005). Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Research, 65, 5153-5162.
92. Kenny, P. A., & Bissell, M. J. (2003). Tumor reversion: Correction of malignant behavior by microenvironmental cues. International Journal of Cancer, 107, 688-695.
93. Miller, J. C., & Sorensen, A. G. (2005). Imaging biomarkers predictive of disease/therapy outcome: Ischemic stroke and drug development. Progress in Drug Research, 62, 319-356.
94. Arora, A., & Scholar, E. M. (2005). Role of tyrosine kinase inhibitors in cancer therapy. Journal of Pharmacology and Experimental Therapeutics, 315, 971-979.
95. Zhong, H., & Bowen, J. P. (2006). Antiangiogenesis drug design: Multiple pathways targeting tumor vasculature. Current Medicinal Chemistry, 13, 849-862.
96. Meric, J. B., Rottey, S., Olaussen, K., Soria, J. C., Khayat, D., Rixe, O., et al. (2006). Cyclooxygenase-2 as a target for anticancer drug development. Critical Reviews in Oncology/Hematology, 59, 51-64.
97. Aggarwal, B. B., Shishodia, S., Sandur, S. K., Pandey, M. K., & Sethi, G. (2006). Inflammation and cancer: How hot is the link? Biochem Pharmacol.
98. Kobayashi, H., & Lin, P. C. (2006). Antiangiogenic and radiotherapy for cancer treatment. Histology and Histopathology, 21, 1125-1134.
99. Grosch, S., Maier, T. J., Schiffmann, S., & Geisslinger, G. (2006). Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. Journal of the National Cancer Institute, 98, 736-747.
100. Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., et al. (2001). Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Medicine, 7, 1194-1201.
101. Vosseler, S., Mirancea, N., Bohlen, P., Mueller, M. M., & Fusenig, N. E. (2005). Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Research, 65, 1294-1305.
102. Kulbe, H., Levinson, N. R., Balkwill, F., & Wilson, J. L. (2004). The chemokine network in cancer-much more than directing cell movement. International Journal of Developmental Biology, 48, 489-496.